Glioma Stem Cells Upregulate CD39 Expression to Escape Immune Response through SOX2 Modulation

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Ectonucleotidase CD39 regulates immune responses in the tumor microenvironment by hydrolyzing extracellular ATP (eATP).
• The specific role of CD39 in promoting immunosuppression by glioma stem cells (GSCs) remains unclear.

Purpose of the Study:

• To investigate the role of CD39 in maintaining an immunosuppressive microenvironment around GSCs.
• To explore the potential of CD39 inhibition as a therapeutic strategy in combination with chemotherapy.

Main Methods:

• Analyzing CD39 expression in GSCs and its effect on extracellular ATP levels.
• Investigating the impact of Adriamycin (ADM) and CD39 inhibition on dendritic cell (DC) phagocytosis.
• Examining the regulatory mechanism of CD39 promoter by SOX2.
• Evaluating the efficacy of combined ADM and CD39 blockade in mouse tumor models.

Main Results:

• Upregulation of CD39 by GSCs decreases extracellular ATP, creating an immunosuppressive microenvironment.
• ADM treatment increases ATP release, enhancing DC phagocytosis of GSCs.
• CD39 inhibition amplifies the ADM-induced increase in extracellular ATP and DC phagocytosis.
• GSCs upregulate CD39 expression via SOX2 binding to its promoter.
• Combined ADM and CD39 blockade in vivo enhanced immune cell infiltration and reduced tumor volume.

Conclusions:

• GSCs utilize CD39 to establish an immunosuppressive tumor microenvironment (TME).
• CD39 inhibition, in combination with chemotherapy, creates a more favorable TME for immunotherapy.
• Targeting CD39 enhances chemotherapy-induced immune responses and could be a promising therapeutic approach.